Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

NCT01630733 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT01630733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01630733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Lead sponsor
Achieve Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
October 24, 2012
Completion date
November 17, 2016
Enrollment
664 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer